These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36943397)

  • 1. P4HA2-mediated HIF-1α stabilization promotes erdafitinib-resistance in FGFR3-alteration bladder cancer.
    Li X; Li Y; Liu B; Chen L; Lyu F; Zhang P; He Q; Cheng L; Liu C; Song Y; Xing Y
    FASEB J; 2023 Apr; 37(4):e22840. PubMed ID: 36943397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer.
    Roubal K; Myint ZW; Kolesar JM
    Am J Health Syst Pharm; 2020 Feb; 77(5):346-351. PubMed ID: 32073123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
    Guercio BJ; Sarfaty M; Teo MY; Ratna N; Duzgol C; Funt SA; Lee CH; Aggen DH; Regazzi AM; Chen Z; Lattanzi M; Al-Ahmadie HA; Brannon AR; Shah R; Chu C; Lenis AT; Pietzak E; Bochner BH; Berger MF; Solit DB; Rosenberg JE; Bajorin DF; Iyer G
    Clin Cancer Res; 2023 Nov; 29(22):4586-4595. PubMed ID: 37682528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erdafitinib for the treatment of metastatic bladder cancer.
    Montazeri K; Bellmunt J
    Expert Rev Clin Pharmacol; 2020 Jan; 13(1):1-6. PubMed ID: 31810398
    [No Abstract]   [Full Text] [Related]  

  • 5. Identifying fibroblast growth factor receptor genetic alterations using RNA-based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment.
    Wang S; Burgess M; Major C; English A; Sweeney M; Hartmann A
    J Pathol Clin Res; 2020 Jul; 6(3):207-214. PubMed ID: 32304281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.
    Weickhardt AJ; Lau DK; Hodgson-Garms M; Lavis A; Jenkins LJ; Vukelic N; Ioannidis P; Luk IY; Mariadason JM
    BMC Cancer; 2022 May; 22(1):478. PubMed ID: 35501832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand.
    D'Angelo A; Bagby S; Galli IC; Bortoletti C; Roviello G
    Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1139-1146. PubMed ID: 32935605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma.
    Bansal P; Dwivedi DK; Hatwal D; Sharma P; Gupta V; Goyal S; Maithani M
    Anticancer Agents Med Chem; 2021; 21(18):2478-2486. PubMed ID: 33475078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma.
    Hosni S; Kilian V; Klümper N; Gabbia D; Sieckmann K; Corvino D; Winkler A; Saponaro M; Wörsdörfer K; Schmidt D; Hahn O; Zanotto I; Bertlich M; Toma M; Bald T; Eckstein M; Hölzel M; Geyer M; Ritter M; Wachten D; De Martin S; Alajati A
    Cancer Res; 2024 Mar; 84(5):725-740. PubMed ID: 38175774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
    Siefker-Radtke AO; Necchi A; Park SH; García-Donas J; Huddart RA; Burgess EF; Fleming MT; Rezazadeh Kalebasty A; Mellado B; Varlamov S; Joshi M; Duran I; Tagawa ST; Zakharia Y; Akapame S; Santiago-Walker AE; Monga M; O'Hagan A; Loriot Y;
    Lancet Oncol; 2022 Feb; 23(2):248-258. PubMed ID: 35030333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-up.
    Loriot Y; O'Hagan A; Siefker-Radtke AO
    Future Oncol; 2024 Feb; 20(5):231-243. PubMed ID: 37916514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors.
    Qin Q; Patel V; Galsky MD
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):503-512. PubMed ID: 32436413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib.
    de Almeida Carvalho LM; de Oliveira Sapori Avelar S; Haslam A; Gill J; Prasad V
    JAMA Netw Open; 2019 Nov; 2(11):e1916091. PubMed ID: 31755953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erdafitinib exerts the anticancer effect on urothelial carcinoma
    Jin YY; Tong SQ; Tong M
    Pharmazie; 2020 May; 75(5):195-197. PubMed ID: 32393427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain
    Franza A; Pirovano M; Giannatempo P; Cosmai L
    Future Oncol; 2022 Jun; 18(19):2455-2464. PubMed ID: 35387485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression.
    Okato A; Utsumi T; Ranieri M; Zheng X; Zhou M; Pereira LD; Chen T; Kita Y; Wu D; Hyun H; Lee H; Gdowski AS; Raupp JD; Clark-Garvey S; Manocha U; Chafitz A; Sherman F; Stephens J; Rose TL; Milowsky MI; Wobker SE; Serody JS; Damrauer JS; Wong KK; Kim WY
    J Clin Invest; 2024 Jan; 134(2):. PubMed ID: 38226620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor receptors across urothelial carcinoma landscape.
    Ertl IE; Shariat SF; Mostafaei H; Ilijazi D; Loriot Y
    Curr Opin Urol; 2020 Jul; 30(4):557-565. PubMed ID: 32452999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy.
    Benjamin DJ; Hsu R
    Front Immunol; 2023; 14():1258388. PubMed ID: 37675102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor receptor (
    Al-Obaidy KI; Cheng L
    J Clin Pathol; 2021 Aug; 74(8):491-495. PubMed ID: 33731335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib.
    Karkera JD; Cardona GM; Bell K; Gaffney D; Portale JC; Santiago-Walker A; Moy CH; King P; Sharp M; Bahleda R; Luo FR; Alvarez JD; Lorenzi MV; Platero SJ
    Mol Cancer Ther; 2017 Aug; 16(8):1717-1726. PubMed ID: 28416604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.